AlloVir (NASDAQ:ALVR) layoffs are in the news after the clinical-stage cell therapy company announced a massive number of job cuts. AlloVir has revealed that a new round of layoffs will have it ...

As of April 24, 2023, the average one-year price target for AlloVir is 22.44. The forecasts range from a low of 16.16 to a high of $31.50. The average price target represents an increase of 544.83% ...

AlloVir (NASDAQ:ALVR) stock is falling hard on Thursday after the company announced the pricing of a public share offering. That offering has AlloVir selling 20 million shares of ALVR stock for $3.75 ...

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP reminds investors that a shareholder filed a class action on behalf of all persons and entities that purchased or otherwise acquired AlloVir, Inc. (NASDAQ: ALVR ...

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of AlloVir, Inc. (NASDAQ: ALVR) and Kalaris Therapeutics is fair to AlloVir shareholders.

AlloVir, Inc. ALVR announced that the FDA has granted Regenerative Medicine Advanced Therapy (“RMAT”) designation to its allogeneic, off-the-shelf, multi-virus-specific T-cell therapy, posoleucel, for ...

ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the posoleucel Phase 3 Studies were ...

or contact Joseph E. Levi, Esq. via email at [email protected] or call (212) 363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit ...